New eczema drug shows promise in phase 3 trial
NCT ID NCT06477835
First seen Apr 02, 2026 · Last updated May 21, 2026 · Updated 8 times
Summary
This study tested a new medication called SIM0718 in 259 adults and teenagers (ages 12-75) with moderate to severe atopic dermatitis (eczema). The goal was to see if it improves skin symptoms like redness and itching compared to a placebo. Participants received either the drug or a dummy treatment, and doctors measured skin clearance and itch reduction over 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University People's Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.